Angiotensin I-Converting Enzyme Inhibitor Improves Reactive Hyperemia in Elderly Hypertensives with Arteriosclerosis Obliterans

Reactive Hyperemia Index Associated With Atherosclerotic Cardiovascular Disease Under Treatment for Lifestyle Diseases

“…Several studies have shown various associations of RHI in night-time blood pressure variant patients [10], non-alcoholic fatty liver disease patients [11], obstructive sleep apnea patients [12] and non-obstructive coronary artery disease patients [13], in addition to major cardiovascular events [14]. Angiotensin I converting enzyme inhibitor [15][16][17], dipeptidyl peptidase-4 inhibitors (DPP-4Is) [18], sodiumglucose co-transporter 2 inhibitors [19] and statin therapy [20] have all been shown to improve endothelial function. For the reasons above, the value of RHI changes due to the underlying diseases and medications, and the cutoff value of RHI for ASCVD has not been determined.…”

Beneficial Effects of Combination Therapy with Angiotensin II Receptor Blocker and Angiotensin-Converting Enzyme Inhibitor on Vascular Endothelial Function

“…Therefore, therapeutic strategies to reduce endothelial dysfunction and arteriosclerosis are required. Several lines of evidence indicate that ACE-Is and ARBs reduce vascular endothelial dysfunction (11)(12)(13)(14)(15) and arteriosclerosis (15,16). Beneficial effects of combination therapy with ACE-I and ARB on endothelial dysfunction have been reported in animal models (17) but not in humans.…”